BOULDER, Colo., Oct. 28, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2014 and hold a conference call to discuss those results on Thursday, October 31, 2013. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.
Conference Call Information
Thursday, October 31, 2013
9:00 a.m. eastern time
Webcast, including Replay and Conference Call Slides:
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions. Novartis began Phase 3 trials evaluating Array-invented MEK162 in patients with NRAS-mutant melanoma in July 2013 and in patients with BRAF-mutant melanoma in October 2013. In addition, Array began a Phase 3 trial evaluating MEK162 in patients with low-grade serous ovarian cancer under the license agreement with Novartis in June 2013. AstraZeneca began a pivotal trial with Array-invented selumetinib in patients with thyroid cancer in May 2013 and began a Phase 3 trial in patients with non-small cell lung cancer in October 2013. Two other wholly-owned drugs, ARRY-520 and ARRY-614, are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. For more information on Array, please go to www.arraybiopharma.com.
Array BioPharma Inc.
SOURCE Array BioPharma Inc.
|Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2014 on February 4, 2014 (2014/1/29)|
|Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2014 And Announces ARRY-520 Development Strategy ()|
|China Distance Education Holdings Limited Reports Financial Results for the First Quarter of Fiscal 2014 (2014/2/19)|
|TSR, Inc. Reports Financial Results for the Fourth Quarter and Fiscal Year Ended May 31, 2013 ()|
|OmniVision Reports Financial Results For the First Quarter of Fiscal 2014 (2013/8/29)|
|China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2014 ()|
|Bridgeline Digital to Report Financial Results for the First Quarter of Fiscal 2014 (2014/2/11)|
|QuinStreet Reports Financial Results for Its First Quarter of Fiscal 2014 ()|
|International Speedway Corporation Reports Financial Results For The First Quarter Of Fiscal 2014 (2014/4/8)|
|Rally Software to Report Financial Results for the Second Quarter of Fiscal 2014 on September 5, 2013 ()|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.